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At primary operation cartilage lesions had undergone a standard-
ized algorithm. All grade IV defects within the mean bearing zone
of the medial femoral condyle (MFC) or medial tibial plateau (MT)
were treated by microfracturing. Grade I or II lesions didn’t un-
dergo any treatment. Grade III lesions had undergone different
modalities: 1999 to 2001 mechanical debridement; 2002 to 2004
no treatments; since 2005 bipolar thermochondroplasty by using
a temperature-controlled device (Paragon, Arthrocare Sweden).
Clinical assessment was made by corrected KOOS (Knee Os-
teoarthritis Outcome Score) and cartilage lesions were graded
accordingly to the guidelines of the ICRS (International Cartilage
Repair Society).
Results: Clinical outcome: In 39.9% resulted good or excellent
and in 45.2% a moderate outcome. The corrected KOOS in-
creased from 46.8±5.4 preoperatively to 73.5±14.1 percent at
follow-up. Patients with grade III lesions who had undergone ther-
mochondroplasty had the best outcome (ﬁgure).
Cartilage lesions: A total of 167 patients had grade III lesions
within the MFC and 61 had a complete grade IV defect. Grade
III defects had undergone mechanical debridement 52-times and
thermochondroplasty 50-times. In 65 patients no treatment was
performed. Mechanical debridement of grade III produced in 32.7%
complete grade IV lesions and only in 3 cases an improvement
into grade II lesions. After thermochondroplasty 29 patients had
a grade II and 14 patients had a grade I lesion in the mean
bearing zone of the MFC. In 2 patients resulted a complete
defect and 5 patients thermochondroplasty was without effect.
The microfracturing of complete grade IV defects produced in 32
patients stabile regenerates but in 29 patients this procedure was
without effect.
Similar results were evaluated after treatment of cartilage lesions
within the mean bearing zone of the TM.
Within the lateral joint compartment and within the femoro-patellar
joint space no increase of cartilage lesions was observed.
The restoration of cartilage lesions was associated with an im-
provement of the clinical outcome.
Conclusions: HTO in combination with arthroscopic surgery can
be effectively in treatment of unicondylar kneeOA. The mild treat-
ment of grade III lesions by thermochondroplasty frequently pro-
duces stabile cartilage areas. Against the mechanical debridement
has no effect compared with a simple joint lavage.
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Purpose: In osteoarthritis (OA), it has long been understood that
cartilage degeneration is accompanied by sclerosis of subchondral
bone. The subsequent stiffening of the bone decreases its capacity
to absorb mechanical impact energy, which might play a role in
the development and/or progression of cartilage degeneration.
Joint distraction as a treatment for advanced ankle OA has been
shown to provide pain relief and improve clinical function, with
some evidence accruing that cartilage repair is involved. However,
the underlying mechanism(s) remain unclear. This study evalu-
ated whether long-term changes in subchondral bone density are
associated with extended joint distraction.
Methods: Twenty-six patients with advanced post-traumatic ankle
OA were treated with joint distraction for three months using an
Ilizarov frame. Follow-up was two years, and clinical outcome
was assessed using the ankle OA scale (AOS). Dual-contrast CT
scans were obtained at baseline (before treatment), and at one-
and two-year follow-ups after treatment, to analyse joint space
width and bone density. The tibia and talus bones were manually
segmented at each time point, and the bone segmentations from
the two follow-up CT scans were registered to the baseline scans
for each patient. The resulting spatial transformations were then
used to bring all CT datasets for a given patient into a common
spatial reference frame, using purpose-written MATLAB code.
Changes in bone density (Hounsﬁeld Units (HU), relative to base-
line) were calculated at a number of discrete locations beneath
the tibial and talar weight-bearing regions. The measurement grid
covered a subchondral patch of nominally 650 mm2, with ∼4000
point measurements per surface (∼0.17mm2/point). Bone density
calculations were performed at 1 mm intervals beneath the bone
surface, along the surface normals and extending subchondrally
up to 8 mm (total of roughly 30,000 sampled point locations for
each bone).
Results: Joint distraction in these patients resulted in a statistically
signiﬁcant long-term decrease in pain (mean value decreased
from 60 to 35, on a scale of 100; p<0.01) and function (mean
decreased from 67 to 36; p<0.01) at two years post-treatment.
These clinical changes were accompanied by changes in bone
density (Figure 1).
The initial subchondral bone density was 569±14 HU for the tibia,
and 490±19 HU for the talus. The average decrease in density
was 133±17 HU (p<0.01) for the tibia and 95±17 HU (p<0.01)
for the talus, one year after treatment. These density changes
persisted two years after treatment (124±16 HU; p<0.01, and
88±18 HU; p<0.01, for tibia and talus, respectively), and they
were not signiﬁcantly different from the bone density one year
after treatment (p=0.11).
Conclusions: Treatment of advanced post-traumatic ankle OA
with three months of joint distraction produced decreases in sub-
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Figure 1. Changes in subchondral bone density from baseline at one and two
years after ankle distraction for individual patients.
chondral bone density that persisted for at least two years of
follow-up. This could lead to a more physiologically normal distribu-
tion of mechanical stresses by the less dense bone, encouraging
cartilage repair activity. As such, these prolonged bone changes
may in part explain the clinical beneﬁts of joint distraction.
This study was ﬁnancially supported by grants from the NIH/
NIAMS (AR048939 and AR055533).
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Purpose: The proteinase-activated receptor-2 (PAR-2), member
of the G protein coupled receptor family, was demonstrated to
be implicated in human osteoarthritis (OA) cartilage catabolism
and subchondral bone remodeling.To validate the results of these
in vitro studies, we investigated the in vivo role of PAR-2 in the
development of cartilage and subchondral bone changes in OA
using a mouse model.
Methods: Osteoarthritis was induced by partial medial menis-
cectomy of the right knee using a microsurgical technique in
C57Bl/6 wild-type (WT) and PAR-2 knock-out (PAR-2 KO) mice.
Knee swelling was measured twice a week for the entire duration
of the study (8 weeks) with a digital calliper. Histological evalua-
tion assessing cartilage structure, cellularity, matrix staining and
remodelling in the deep zone (global score corresponding to the
sum of the different criteria), as well as morphometric evaluation of
the subchondral bone were performed at 4 and 8 weeks and val-
ues compared to control. A comparison between WT (n=9-10 per
group) and PAR-2 KO (n=5-9 per group) mice was also performed.
Results: Knee swelling was observed in the WT immediately fol-
lowing surgery and increased with time (until week 8). The knee
swelling of the PAR-2 KO mice was signiﬁcantly lower (p<0.0001)
at both 4 and 8 weeks post-surgery than the WT group. Both WT
and PAR-2 KO mice demonstrated cartilage damage at 4 and 8
weeks post-surgery; however, lesions were less severe in the PAR-
2 KO mice (p<0.03 on the global score). More speciﬁcally, com-
pared to PAR-2 KO mice, WT mice had more severe alterations of
the cartilage structure at 4 and 8 weeks post-surgery (p<0.0001
and p<0.02, respectively), a higher hypocellularity (p<0.003), and
a signiﬁcant loss of cartilage (p<0.04) as shown by cartilage thick-
ness measurement. Yet, no signiﬁcant differences in the structural
changes in the deep zone of cartilage and in the subchondral
bone were found in either WT or PAR-2 KO mice. However, con-
trol (unoperated) PAR-2 KO mice had less bone surface than the
autologous WT mice (p<0.04).
Conclusions: This study is the ﬁrst to demonstrate the in vivo
implication of PAR-2 in the development of experimental OA,
thus conﬁrming its involvement in OA structural changes. It also
showed that PAR-2 plays a role on subchondral bone that needs
to be further explored. Consequently, these ﬁndings reinforce the
therapeutic potential of a PAR-2 antagonist for the treatment of OA.
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Purpose: Synovitis (as deﬁned by hypertrophy and effusion) is
common in osteoarthritis and may be important in both pain
and structural progression. In addition, chondroitin sulphate (CS)
treatment has been associated with a signiﬁcant decrease in
the incidence of joint swelling, effusion or both. The aim of this
study was to assess the efﬁcacy of CS alone or in combination
with glucosamine sulfate (GS) on synovitis in patients with knee
osteoarthritis (KOA).
Methods: Retrospective study involving 115 outpatients with syn-
ovitis who received CS 800 mg (N=36) (Condrosan®, Bioibérica
S.A., Barcelona), CS 800 mg + SG 1500 mg (N=41) (Cartisorb®,
Bioibérica S.A., Barcelona) or acetaminophen (ACET) 500 mg
(N= 38) for their KOA on a daily basis for a 6-month period.
Synovitis was measured in the suprapatellar recess using ultra-
sonography (US) equipment with a high frequency linear array.
The maximal synovial thickness and effusion depth were mea-
sured in millimeters using the longitudinal axis. Synovitis was
deﬁned as present in measures ≥4 mm. Furthermore, knee pain
according to Huskisson’s VAS, extra acetaminophen consumption
and the presence of meniscal extrusion and Baker’s cyst were
also assessed. Patient’s follow-up was performed after 1, 2, 3 and
6 months of treatment.
Results: From the 115 included subjects, 111 (96,5%) were
female, had a mean age (SD) of 62,4 (10,8) years, mean BMI
(SD) of 27,4 (4,5) kg/m2, 20 (17,4%) presented Baker’s cyst and
13 (11,3%) meniscal extrusion. The mean synovitis (SD) was 6,3
(1,3) mm and the mean knee pain (SD) was 6,5 (1,8) mm. Patients
in all groups had similar baseline characteristics.
Among all the included subjects, a positive correlation between
BMI and the size of synovitis (r=0,138; p=0,002) and knee pain
(r=0,136; p=0,003) was noted. In addition, a positive correlation
between synovitis and knee pain (r=0,385; p=0,000) was also
detected.
Regarding US assessments, the three treatment groups experi-
enced a decrease in synovitis over time. However, patients treated
with SYSADOAs reached physiological mean values after the
second month of treatment. This improvement in synovitis was
maintained in the course of treatment with a mean synovitis (SD)
of 3,2 (2,7) mm in the CS group and of 2,9 (2,6) mm in the
CS+SG group after 6 months of treatment. Multiple comparisons
between groups, showed a signiﬁcant decrease in synovitis after
SYSADOA therapy vs ACET treatment after the ﬁrst month of
follow-up.Statistical analysis demonstrated a faster decrease in
knee pain with CS vs ACET (p= 0,000) and in the CS + SG
group vs ACET (p=0,000). Analysis at each visit for the decrease
in pain scores showed that the differences between CS+ SG vs
ACET were signiﬁcant after the ﬁrst month of treatment (p=0,037)
and between CS vs ACET after the second month of treatment
(p=0,017).
